ATE228367T1 - Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein - Google Patents

Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein

Info

Publication number
ATE228367T1
ATE228367T1 AT99926749T AT99926749T ATE228367T1 AT E228367 T1 ATE228367 T1 AT E228367T1 AT 99926749 T AT99926749 T AT 99926749T AT 99926749 T AT99926749 T AT 99926749T AT E228367 T1 ATE228367 T1 AT E228367T1
Authority
AT
Austria
Prior art keywords
genistein
carnitine
osteoporosis
prophylaxis
treatment
Prior art date
Application number
AT99926749T
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Application granted granted Critical
Publication of ATE228367T1 publication Critical patent/ATE228367T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT99926749T 1998-06-23 1999-06-17 Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein ATE228367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
PCT/IT1999/000174 WO1999066913A2 (en) 1998-06-23 1999-06-17 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein

Publications (1)

Publication Number Publication Date
ATE228367T1 true ATE228367T1 (de) 2002-12-15

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926749T ATE228367T1 (de) 1998-06-23 1999-06-17 Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein

Country Status (27)

Country Link
US (1) US6335038B1 (de)
EP (1) EP1089742B1 (de)
JP (1) JP4430233B2 (de)
KR (1) KR20010071541A (de)
CN (1) CN1306434A (de)
AR (1) AR018924A1 (de)
AT (1) ATE228367T1 (de)
AU (1) AU755272B2 (de)
BR (1) BR9911440A (de)
CA (1) CA2334875C (de)
DE (1) DE69904172T2 (de)
DK (1) DK1089742T3 (de)
EE (1) EE200000741A (de)
ES (1) ES2188177T3 (de)
HU (1) HU224957B1 (de)
IL (1) IL140163A0 (de)
IS (1) IS5764A (de)
IT (1) IT1299191B1 (de)
MA (1) MA26655A1 (de)
NO (1) NO20006431L (de)
NZ (1) NZ508877A (de)
PL (1) PL192118B1 (de)
PT (1) PT1089742E (de)
SK (1) SK19292000A3 (de)
TN (1) TNSN99132A1 (de)
TR (1) TR200003735T2 (de)
WO (1) WO1999066913A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
AU2001245977A1 (en) * 2000-03-23 2001-10-03 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of menopause
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
IT1317079B1 (it) 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
BRPI0208103B8 (pt) * 2001-03-15 2021-05-25 Dsm Ip Assets Bv composição para a prevenção de osteoporose compreendendo uma combinação de isoflavonas e ácidos graxos poliinsaturados, seu uso, composição dietética, bem como formulação galênica que compreende a dita composição dietética
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
EP1474129A1 (de) * 2002-02-15 2004-11-10 N.V. Nutricia Verwendung von genistein zur herstellung eines medikaments zur behandlung von osteoporose und obesität und zusammenstezungen enthaltend genistein mit vitamin d und k
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
JP5102434B2 (ja) * 2002-09-09 2012-12-19 ネステク ソシエテ アノニム 皮膚品質を改良するための経口投与可能な組成物
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
CN103211806B (zh) * 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 新颖的营养药物性组合物及其用途
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
US20080305094A1 (en) * 2004-01-28 2008-12-11 Nestec S.A. Nutritional Composition for Improving Skin Condition and Preventing Skin Diseases
KR100739280B1 (ko) * 2004-02-03 2007-07-12 가부시끼가이샤 고또스기 운남 홍두삼 유래 이소탁시레시놀을 성분으로 하는골다공증 치료ㆍ예방약
EP2208422B1 (de) * 2004-03-17 2015-11-25 Nestec S.A. Zubereitungen und Verfahren zur Minderung oder Prävention von Adiposität
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
CA2592389C (en) 2004-12-29 2013-05-14 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
EP1841421A4 (de) * 2005-01-10 2008-01-02 Hormos Medical Ltd Verwendung von lignan zur herstellung einer zusammensetzung zur prävention oder linderung von symptomen im zuammenhang mit östrogenmangel
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
AU2006268787B2 (en) * 2005-07-08 2012-02-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of a combination comprising L-carnitine or alkanoyl L-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
AU2006267068B2 (en) 2005-07-14 2011-01-06 Hill's Pet Nutrition, Inc. Method for prolonging the life of animals
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
KR20080068850A (ko) * 2005-10-14 2008-07-24 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도
JP2009514824A (ja) 2005-11-02 2009-04-09 ネステク ソシエテ アノニム 雄の哺乳動物における体脂肪の蓄積を低減するためのイソフラボン組成物及びその使用方法
CN101389328B (zh) 2006-02-28 2013-04-24 雀巢技术公司 诱导骨生长和抑制骨流失的组合物和方法
CA2643973A1 (en) 2006-02-28 2007-09-07 Council Of Scientific And Industrial Research Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof
WO2007116052A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising dha and genistein for enhancing skin properties
EP2004169B1 (de) * 2006-04-12 2012-08-08 Unilever PLC Orale zusammensetzung mit einer mehrfach ungesättigten fettsäure und salicylsäure zur erzielung einer entzündungshemmenden wirkung in der haut
PL2189155T3 (pl) * 2006-04-12 2016-07-29 Unilever Nv Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
PT2343292E (pt) 2008-09-10 2014-11-04 Kaken Pharma Co Ltd Novo derivado de prostaglandina i2
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
JP2012508267A (ja) * 2008-11-11 2012-04-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ セルライトの処置に有用な化合物
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
JP2013530170A (ja) * 2010-06-16 2013-07-25 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 神経組織における神経発生を増大させるための方法における使用のためのアセチル−カルニチン
WO2012011572A1 (ja) * 2010-07-23 2012-01-26 国立大学法人大阪大学 拡張不全型心不全治療薬
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
EP1021177A4 (de) * 1997-02-04 2002-05-15 John V Kosbab Zusammensetzungen und verfahren zur verhütung und behandlung von vaskulär-degeneratieve krankheiten

Also Published As

Publication number Publication date
JP4430233B2 (ja) 2010-03-10
CA2334875A1 (en) 1999-12-29
CA2334875C (en) 2009-05-12
EE200000741A (et) 2002-04-15
IT1299191B1 (it) 2000-02-29
KR20010071541A (ko) 2001-07-28
NO20006431L (no) 2001-02-22
EP1089742A2 (de) 2001-04-11
IL140163A0 (en) 2002-02-10
ES2188177T3 (es) 2003-06-16
US6335038B1 (en) 2002-01-01
PT1089742E (pt) 2003-04-30
BR9911440A (pt) 2001-03-20
HU224957B1 (en) 2006-04-28
DE69904172T2 (de) 2003-08-28
PL192118B1 (pl) 2006-09-29
DE69904172D1 (de) 2003-01-09
MA26655A1 (fr) 2004-12-20
HUP0102879A3 (en) 2002-12-28
AR018924A1 (es) 2001-12-12
EP1089742B1 (de) 2002-11-27
TNSN99132A1 (fr) 2005-11-10
CN1306434A (zh) 2001-08-01
ITRM980417A1 (it) 1999-12-23
ITRM980417A0 (it) 1998-06-23
HUP0102879A2 (hu) 2002-03-28
AU4390999A (en) 2000-01-10
DK1089742T3 (da) 2003-03-24
NZ508877A (en) 2002-09-27
AU755272B2 (en) 2002-12-05
PL345030A1 (en) 2001-11-19
IS5764A (is) 2000-12-08
WO1999066913A2 (en) 1999-12-29
WO1999066913A3 (en) 2000-04-20
TR200003735T2 (tr) 2001-03-21
NO20006431D0 (no) 2000-12-15
JP2002518437A (ja) 2002-06-25
SK19292000A3 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
ATE228367T1 (de) Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein
ATE262892T1 (de) Verwendung einer zusammensetzung enthaltend capsaicin oder resiniferatoxin zur behandlung des reizdarmsyndroms
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
ATE247464T1 (de) Neue fettanaloge zur behandlung der fettleibigkeit
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
EP1446114A4 (de) Zusammensetzungen und verfahren zur behandlung von osteoporose
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
EP1169319A4 (de) Methoden und zusammensetzungen zum abbau und /oder zur hemmung von tyrosin-kinasen der her-familie
DE69109401D1 (de) Wässrige Zusammensetzungen zur Behandlung von porösen Substraten.
DE69916629D1 (de) Taurolidin und/oder taurultam zur behandlung von infektiösen ulcera oder gastritis
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
ATE230597T1 (de) Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
HUP0302309A3 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity and for preparation of pharmaceutical compositions containing them
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
DE69902127D1 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
DE69231384D1 (de) Zusammensetzungen zur behandlung des chronischen erschöpfungs-syndroms

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1089742

Country of ref document: EP